FilingSEC EDGAR8-K
GRI Bio Announces Positive Phase 2a Data for GRI-0621 in IPF
· SEC accepted
StagePhase 2a
Filing content
GRI Bio announced positive biomarker and lung function data from its Phase 2a study of GRI-0621 in patients with idiopathic pulmonary fibrosis. The results were presented at the European Respiratory Society Congress.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…